Results 91 to 100 of about 85,247 (140)

Loss of nsp14-exonuclease activity impairs the replication, proofreading, fitness, and pathogenesis of SARS-CoV-2. [PDF]

mBio
Anderson-Daniels J, Diefenbacher MV, Yount BL, Meganck RM, Tse LV, Burke KN, Miranda HA, Scobey DT, Lu X, Stevens L, Dinnon KH, Chapman NS, Pajon C, Powers JM, Nguyen C, Graham RL, Heaton NS, Baric RS, Denison MR, Sheahan TP.   +19 more
europepmc   +1 more source

Treatment Duration of Each Anti-COVID-19 Agent Used in a Tertiary Hospital in Japan. [PDF]

Cureus
Seki M, Enami K.
europepmc   +1 more source

Inhibitory effects of molnupiravir on Crimean-Congo hemorrhagic fever virus polymerase. [PDF]

NAR Mol Med
Sloan A, Gordon CJ, Prévost J, Audet J, Fulton K, Woolner E, Chang MH, Walker SM, Tchesnokov EP, Das K, Safronetz D, Götte M.   +11 more
europepmc   +1 more source

Prodrug strategies in developing antiviral nucleoside analogs. [PDF]

RSC Med Chem
Suresh RR, Abuduani T, Kasthuri M, Chen Z, Tber Z, Loubidi M, Zhang H, Zhou L, Zhou S, Li C, Kumari A, Tao S, Wiseman JM, Hurwitz SJ, Amblard F, Schinazi RF.   +15 more
europepmc   +1 more source

A SARS-CoV-2 M^pro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibility. [PDF]

Nat Commun
Min SC, Seo JJ, Jeong JH, Kim BK, Park JH, Lee JR, Lee DG, Lee GC, An SH, Baek YH, Choi YK, Choo H, Park HY, Kim G, Jeon B, Shin SC, Song MS.   +16 more
europepmc   +1 more source

The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection

Antiviral Research, 2023
Trevor Brasel
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment

Molecular Pharmaceutics, 2023
The pharmacokinetic alteration of an antimicrobial medication leading to sub-therapeutic plasma level can aid in the emergence of resistance, a global threat nowadays. In this context, molnupiravir (prodrug of EIDD-1931) is the most efficacious orally against corona virus disease (COVID-19). In addition to drug-drug interaction, the pharmacokinetics of
Debaraj Mukherjee, Utpal Nandi, Priya Wazir   +2 more
exaly   +3 more sources

Dehydration-Driven Nanomechanical Responses of the Antiviral Drug EIDD-1931

Crystal Growth and Design, 2023
Surojit Bhunia, C Malla Reddy, Mangalampalli Srn Kiran   +2 more
exaly   +2 more sources

β-D-N4-hydroxycytidine (NHC, EIDD-1931) inhibits chikungunya virus replication in mosquito cells and ex vivo Aedes aegypti guts, but not when ingested during blood-feeding

Antiviral Research
Chikungunya virus (CHIKV) is a mosquito-borne virus transmitted by Aedes mosquitoes. While there are no antiviral therapies currently available to treat CHIKV infections, several licensed oral drugs have shown significant anti-CHIKV activity in cells and in mouse models. However, the efficacy in mosquitoes has not yet been assessed.
Albin Fontaine, Lanjiao Wang, Leen Delang   +2 more
exaly   +5 more sources

The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection.

Antiviral research, 2023
The unprecedented magnitude of the 2013-2016 Ebola virus (EBOV) epidemic in West Africa resulted in over 11 000 deaths and spurred an international public health emergency. A second outbreak in 2018-2020 in DRC resulted in an additional >3400 cases and nearly 2300 deaths (WHO, 2020). These large outbreaks across geographically diverse regions highlight
Gregory R, Bluemling, Shuli, Mao, Michael G, Natchus, Wendy, Painter, Sabue, Mulangu, Mark, Lockwood, Abel, De La Rosa, Trevor, Brasel, Jason E, Comer, Alexander N, Freiberg, Alexander A, Kolykhalov, George R, Painter   +11 more
openaire   +1 more source